Synonyms
- Buprenex®
- Suboxone®
- Subutex®
|
|
Expected Turnaround Time
3 - 6 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Documents
Specimen Requirements
Specimen
Serum or plasma
|
Serum |
|
Serum or plasma |
Volume
3 mL
|
|
|
3 mL |
Minimum Volume
0.5 mL
Container
Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes are not recommended
|
Red-top |
|
Red-top (no additive) tube or green-top (heparin) tube; gel-barrier tubes are not recommended |
Collection
Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible.
|
|
|
Transfer separated serum or plasma to a plastic transport tube. Trough levels are most reproducible. |
Storage Instructions
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen.
|
|
|
Submission/transport (<3 days): Room temperature. For storage beyond three days, specimen should be refrigerated or frozen. |
Stability Requirements
| Temperature | Period |
|---|---|
| Room temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 14 days |
Test Details
Use
This test is used for therapeutic drug management.
|
Buprenorphine is used in the management of moderate to severe chronic pain. Half-life elimination: IV: 2.2 to 3 hours, Sublingual tablet: approximately 37 hours, Transdermal patch: approximately 26 hours Time to peak plasma: Sublingual: 30 minutes to 1 hour |
|
This test is used for therapeutic drug management. |
Limitations
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Reference Interval
Buprenorphine: 1.00–10.00 ng/mL; norbuprenorphine: not established
|
|
|
Buprenorphine: 1.00–10.00 ng/mL; norbuprenorphine: not established |
LOINC® Map
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf